Zhu Jichao, Zhang Jiliang, Gu Chao
Clinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China.
Clinical Laboratory, Lishui People's Hospital, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, Zhejiang, China.
World J Surg Oncol. 2025 Jul 16;23(1):283. doi: 10.1186/s12957-025-03949-1.
The effect of soluble programmed cell death 1 ligand 1 (sPD-L1) on the prognosis of colorectal cancer (CRC) has been extensively explored; however, the results remain controversial. Therefore, we performed a meta-analysis to determine its exact function in predicting CRC prognosis.
We retrieved relevant data from the Web of Science, PubMed, Embase, and Cochrane Library databases from their inception to February 24, 2025. We computed combined hazard ratios (HRs) and 95% confidence intervals (CIs) to estimate the value of sPD-L1 in predicting overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in CRC.
Six studies involving a total of 773 patients were included. The integrated results revealed that higher sPD-L1 levels were significantly associated with unfavorable OS (HR = 2.19, 95%CI = 1.16‒4.15; p = 0.016) and DFS/PFS (HR = 3.14, 95%CI = 1.88‒5.24; p < 0.001) in CRC. However, sPD-L1 was not markedly associated with sex (OR = 1.28, 95%CI = 0.52-3.14; p = 0.596), T stage (OR = 0.65, 95%CI = 0.33‒1.28; p = 0.210), TNM stage (OR = 0.99, 95%CI = 0.57‒1.74; p = 0.976) and lymph node metastasis (OR = 0.86, 95%CI = 0.46‒1.58; p = 0.620) in CRC.
Elevated sPD-L1 levels could serve as a critical factor in predicting both unfavorable OS and DFS/PFS in patients with CRC.
可溶性程序性细胞死亡蛋白1配体1（sPD-L1）对结直肠癌（CRC）预后的影响已得到广泛研究；然而，结果仍存在争议。因此，我们进行了一项荟萃分析，以确定其在预测CRC预后方面的确切作用。
我们从Web of Science、PubMed、Embase和Cochrane图书馆数据库中检索了从数据库建立至2025年2月24日的相关数据。我们计算合并风险比（HRs）和95%置信区间（CIs），以评估sPD-L1在预测CRC总生存期（OS）、无病生存期（DFS）和无进展生存期（PFS）方面的价值。
纳入了6项研究，共773例患者。综合结果显示，较高的sPD-L1水平与CRC患者不良的OS（HR = 2.19，95%CI = 1.16‒4.15；p = 0.016）以及DFS/PFS（HR = 3.14，95%CI = 1.88‒5.24；p < 0.001）显著相关。然而，sPD-L1与CRC患者的性别（OR = 1.28，95%CI = 0.52 - 3.14；p = 0.596）、T分期（OR = 0.65，95%CI = 0.33‒1.28；p = 0.210）、TNM分期（OR = 0.99，95%CI = 0.57‒1.74；p = 0.976）和淋巴结转移（OR = 0.86，95%CI = 0.46‒1.58；p = 0.620）无明显关联。
sPD-L1水平升高可能是预测CRC患者不良OS和DFS/PFS的关键因素。
